Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/34959
Title: Methodology of a new inflammatory arthritis registry: TReasure
Authors: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Ramotoloji Bilim Dalı.
0000-0003-0298-4157
Dalkılıç, Hüseyin Ediz
Pehlivan, Yavuz
Coşkun, Belkıs Nihan
Yağız, Burcu
AAG-8227-2021
AAG-7155-2021
57203462896
13205593600
55646165400
57203458191
Keywords: General & internal medicine
Rheumatoid arthritis
Spondyloarthritis
Disease-modifying antirheumatic drugs
Registry
TReasure
Society classification criteria
Necrosis factor therapy
Rheumatoid-arthritis
Ankylosing-spondylitis
Disease-activity
Psoriatic-arthritis
Clinical history
Back-pain
Spondyloarthritis
Validation
Issue Date: 11-Aug-2018
Publisher: TÜBİTAK
Citation: Kalyoncu, U. vd. (2018). ''Methodology of a new inflammatory arthritis registry: TReasure''. Turkish Journal of Medical Sciences, 48(4), 856-861.
Abstract: Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
Description: Çalışmada 34 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.
URI: https://doi.org/10.3906/sag-1807-200
https://journals.tubitak.gov.tr/medical/vol48/iss4/23/
http://hdl.handle.net/11452/34959
ISSN: 1300-0144
1303-6165
Appears in Collections:Scopus
TrDizin
Web of Science

Files in This Item:
File Description SizeFormat 
Dalkılıç_vd_2018.pdf131.95 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons